1,153
Views
47
CrossRef citations to date
0
Altmetric
Letter

Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity

, , , , , , & show all
Pages 154-163 | Received 05 Oct 2012, Accepted 29 Nov 2012, Published online: 09 Jan 2013
 

Abstract

Pharmacological ascorbate, via its oxidation, has been proposed as a pro-drug for the delivery of H2O2 to tumors. Pharmacological ascorbate decreases clonogenic survival of pancreatic cancer cells, which can be reversed by treatment with scavengers of H2O2. The goal of this study was to determine if inhibitors of intracellular hydroperoxide detoxification could enhance the cytotoxic effects of ascorbate. Human pancreatic cancer cells were treated with ascorbate alone or in combination with inhibitors of hydroperoxide removal including the glutathione disulfide reductase inhibitor 1,3 bis (2-chloroethyl)-1-nitrosurea (BCNU), siRNA targeted to glutathione disulfide reductase (siGR), and 2-deoxy-D-glucose (2DG), which inhibits glucose metabolism. Changes in the intracellular concentration of H2O2 were determined by analysis of the rate of aminotriazole-mediated inactivation of endogenous catalase activity. Pharmacological ascorbate increased intracellular H2O2 and depleted intracellular glutathione. When inhibitors of H2O2 metabolism were combined with pharmacological ascorbate the increase in intracellular H2O2 was amplified and cytotoxicity was enhanced. We conclude that inclusion of agents that inhibit cellular peroxide removal produced by pharmacological ascorbate leads to changes in the intracellular redox state resulting in enhanced cytotoxicity.

Declaration of interest

The authors report no declarations of interest. The author alone are responsible for the content and writing of the paper.

This research was supported by NIH grant U01 CA166800, the Department of Veterans Affairs Medical Research Service, and the Susan L. Bader Foundation of Hope. TJvE had support from NIH P42 ES013661, Training Core; JRW had support from NIH T32CA078586 and NIH R01GM073929. The content is solely the responsibility of the authors and does not represent views of the Department of Veterans Affairs or the NIH.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.